Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817320 · ClinicalTrials.gov registry record · Phase 1
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
A Phase 1 study of ALL, Childhood and Lymphoblastic Leukemia, Acute, Childhood, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 18
- Study locations
NCT03817320 is a Phase 1 study of ALL, Childhood and Lymphoblastic Leukemia, Acute, Childhood that is active but no longer recruiting, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 24 participants, below the 51-participant average among 4 other ALL, Childhood trials with a reported enrollment target (53% lower). The trial reports 18 study locations across 14 states.
The verdict
NCT03817320, a Phase 1 study of ALL, Childhood and Lymphoblastic Leukemia, Acute, Childhood, is active but no longer recruiting, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Ixazomib
- DRUG Asparaginase
Study Locations (18)
Texas
- University of Texas, Southwestern - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital/Baylor University - Houston
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital Orange County - Orange
Ohio
- University Hospitals Seidman Cancer Center - Cleveland
- Nationwide Children's Hospital - Columbus
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of Miami - Miami
Georgia
- Children's Healthcare of Atlanta - Atlanta
Michigan
- C.S. Mott Children's Hospital - Ann Arbor
Minnesota
- Children's Hospital and Clinics of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817320
The ClinicalTrials.gov registry entry for NCT03817320 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 4 other ALL, Childhood trials with a reported enrollment target (53% lower). The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with ALL, Childhood appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT03817320 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT03817320 about?
NCT03817320 is a clinical study titled "PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma". This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
What is the current status of trial NCT03817320?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-02-12. Estimated completion is 2025-06-30.
What conditions does trial NCT03817320 study?
This clinical trial studies the following conditions: ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Childhood.
What interventions are being tested in trial NCT03817320?
The interventions under investigation include: Doxorubicin (DRUG), Dexamethasone (DRUG), Vincristine (DRUG), Ixazomib (DRUG), Asparaginase (DRUG).
Who is sponsoring clinical trial NCT03817320?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817320 being conducted?
This trial has 18 study locations across California, District of Columbia, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ALL, Childhood
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
RECRUITING · Phase 1
-
Childhood Cancer Survivors' Affective Response to Exercise
RECRUITING
-
Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.